Definium Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$166.3M | -$103.9M | -$93.9M | -$66.3M | -$93.9M |
| Operating expenses | $166.3M | $103.9M | $93.9M | $66.3M | $93.9M |
| Cash from operations | -$131.6M | -$79.1M | -$64.4M | -$50.1M | -$45.8M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $440.1M | $302.2M | $124.5M | $170.0M | $164.0M |
| Total liabilities | $107.8M | $60.7M | $46.4M | $19.1M | $12.3M |
| Total debt | $41.0M | $22.0M | $15.0M | — | — |
Shares outstanding 109.1M · Free float 97.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.